What's Next for Endava plc Shareholders After 24.37% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline

Endava ADS fell $0.68, or 24.37%, to $2.11 on September 22, 2026, after the company announced its CFO had been placed on administrative leave pending an independent investigation into accounting treatment of certain customer and supplier agreements. A securities class action complaint alleges investors were misled during September 4, 2025–September 21, 2026, including about accounting review, delayed FY2026 results, and internal controls; the allegations have not been adjudicated. Investors may seek lead-plaintiff status by November 30, 2026, and no class has been certified.

Analysis

The litigation filing is not the incremental risk; the audit committee investigation and any resulting accounting, reporting, or control changes are. The complaint’s claims remain allegations, and the release does not establish misstatement or quantify exposure. Still, uncertainty around customer and supplier agreement accounting can impair confidence in reported revenue and timing, while delayed audited results would extend the period in which investors cannot underwrite the business on clean figures.

Near term (days): legal-advertising headlines add little fundamental information beyond the disclosed investigation, so a fresh short solely on this release risks chasing a sharp repricing. Over 1–3 months, the key catalysts are publication of delayed results, an investigation update, auditor commentary, and any formal restatement or control-deficiency disclosure; the November 30 lead-plaintiff deadline is not itself an operating catalyst. Over 6–18 months, confirmed revenue adjustments or weakened customer confidence could pressure bookings and drive work toward larger IT-services providers such as Accenture, Cognizant, EPAM Systems, or Globant—but no displacement is established.

Contrarian read: the market may be conflating an investigation with proven fraud, making the legal claim alone a poor short thesis. Conversely, a clean resolution may not restore credibility quickly if reporting is delayed or controls are deemed ineffective. Verify the cited share-price data against the tape and review company filings before sizing. Thesis improves with a restatement, auditor resignation, or adverse control finding; it weakens with timely audited reporting and a specific, bounded resolution without material adjustments.

Key Decisions for Investors

• Do not initiate a short based only on the plaintiff-firm announcement. For existing DAVA exposure, consider reducing gross risk or using a defined-risk hedge until audited results and the investigation status are clearer.
• Set an event-driven alert for delayed FY2026 results, quantified accounting adjustments, auditor language, and internal-control disclosures. Treat the November 30 lead-plaintiff deadline as a legal-process date, not a standalone trading catalyst.
• Keep Accenture, Cognizant, EPAM Systems, and Globant on a relative-strength watchlist rather than buying them on presumed share gains; look for evidence of customer or booking transfers before positioning for competitive capture.